Literature DB >> 19417770

Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.

Manisha Pandey1, Silvana Sekuloski, Michael R Batzloff.   

Abstract

Infections caused by group A streptococcus (GAS) represent a public health problem in both developing and developed countries. The current available methods of prevention are either inadequate or ineffective, which is highlighted by the resurgence in invasive GAS infections over the past two decades. The management of GAS and associated diseases requires new and improved approaches. This review discusses various potential approaches in controlling GAS infections, ranging from prophylactic vaccines to antibody immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417770     DOI: 10.1038/icb.2009.29

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  4 in total

1.  Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules.

Authors:  Luiza Guilherme; Martha P Alba; Frederico Moraes Ferreira; Sandra Emiko Oshiro; Fabio Higa; Manuel E Patarroyo; Jorge Kalil
Journal:  J Biol Chem       Date:  2010-12-17       Impact factor: 5.157

2.  Isopeptide bonds mechanically stabilize spy0128 in bacterial pili.

Authors:  Bo Wang; Shijun Xiao; Scott A Edwards; Frauke Gräter
Journal:  Biophys J       Date:  2013-05-07       Impact factor: 4.033

3.  Biological Characterization and Inhibition of Streptococcus pyogenes ZUH1 Causing Chronic Cystitis by Crocus sativus Methanol Extract, Bee Honey Alone or in Combination with Antibiotics: An In Vitro Study.

Authors:  Seham Abdel-Shafi; Abdul-Raouf Al-Mohammadi; Sara Hamdi; Ahmed H Moustafa; Gamal Enan
Journal:  Molecules       Date:  2019-08-09       Impact factor: 4.411

Review 4.  Streptococcal toxic shock syndrome in the intensive care unit.

Authors:  Marylin Schmitz; Xavier Roux; Benedikt Huttner; Jérôme Pugin
Journal:  Ann Intensive Care       Date:  2018-09-17       Impact factor: 6.925

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.